Andreas Baumann

1.2k total citations
31 papers, 880 citations indexed

About

Andreas Baumann is a scholar working on Immunology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Andreas Baumann has authored 31 papers receiving a total of 880 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 11 papers in Molecular Biology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Andreas Baumann's work include Monoclonal and Polyclonal Antibodies Research (11 papers), Biosimilars and Bioanalytical Methods (10 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Andreas Baumann is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (11 papers), Biosimilars and Bioanalytical Methods (10 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Andreas Baumann collaborates with scholars based in Germany, United States and Switzerland. Andreas Baumann's co-authors include Jennifer Sims, Saileta Prabhu, Leslie J. Dickmann, Dietrich Tuerck, Inge A. Ivens, Thomas J. Humphries, Lisa A. Michaels, Prasad Mathew, Thomas McDonald and W. Kuhnz and has published in prestigious journals such as Blood, Nature reviews. Immunology and Carcinogenesis.

In The Last Decade

Andreas Baumann

31 papers receiving 848 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas Baumann Germany 16 304 191 186 177 121 31 880
Jiajun Liu China 17 390 1.3× 224 1.2× 70 0.4× 162 0.9× 171 1.4× 68 1.3k
Michèle Masquelier Sweden 17 427 1.4× 79 0.4× 90 0.5× 88 0.5× 218 1.8× 34 962
Lisa M. Chelstrom United States 16 272 0.9× 213 1.1× 126 0.7× 125 0.7× 181 1.5× 33 907
Jeff X. Zhou China 18 581 1.9× 214 1.1× 75 0.4× 58 0.3× 312 2.6× 35 1.3k
Jun Ho Yi South Korea 22 514 1.7× 126 0.7× 67 0.4× 85 0.5× 552 4.6× 88 1.5k
Renta Hutabarat United States 12 1000 3.3× 216 1.1× 60 0.3× 236 1.3× 74 0.6× 22 1.7k
Hans R. Hendriks Netherlands 21 580 1.9× 259 1.4× 63 0.3× 71 0.4× 321 2.7× 49 1.3k
Lauren Price United States 13 210 0.7× 54 0.3× 85 0.5× 49 0.3× 153 1.3× 22 582
Robert J. Fram United States 25 903 3.0× 79 0.4× 106 0.6× 292 1.6× 598 4.9× 82 1.6k
Xiaoke Huang United States 17 407 1.3× 98 0.5× 43 0.2× 51 0.3× 166 1.4× 27 957

Countries citing papers authored by Andreas Baumann

Since Specialization
Citations

This map shows the geographic impact of Andreas Baumann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Baumann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Baumann more than expected).

Fields of papers citing papers by Andreas Baumann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Baumann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Baumann. The network helps show where Andreas Baumann may publish in the future.

Co-authorship network of co-authors of Andreas Baumann

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Baumann. A scholar is included among the top collaborators of Andreas Baumann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Baumann. Andreas Baumann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baumann, Andreas, et al.. (2019). Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction. European Journal of Pharmaceutical Sciences. 130. 11–20. 25 indexed citations
2.
Ulrich, Peter, Andreas Baumann, Adam Hey, et al.. (2018). Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing. Regulatory Toxicology and Pharmacology. 94. 91–100. 6 indexed citations
3.
Baumann, Andreas, Sven Kronenberg, Lolke de Haan, et al.. (2016). Non-clinical Safety Evaluation of Biotherapeutics – Challenges, Opportunities and new Insights. Regulatory Toxicology and Pharmacology. 80. S1–S14. 15 indexed citations
4.
Baumann, Andreas, et al.. (2016). Leverage nonclinical development of bispecifics by translational science. Drug Discovery Today Technologies. 21-22. 95–102. 3 indexed citations
5.
Brennan, Frank R., Andreas Baumann, Lolke de Haan, et al.. (2015). Nonclinical safety testing of biopharmaceuticals – Addressing current challenges of these novel and emerging therapies. Regulatory Toxicology and Pharmacology. 73(1). 265–275. 13 indexed citations
6.
Baumann, Andreas, Kelly M. Flagella, Roy Forster, et al.. (2014). New challenges and opportunities in nonclinical safety testing of biologics. Regulatory Toxicology and Pharmacology. 69(2). 226–233. 19 indexed citations
7.
Baumann, Andreas, Dietrich Tuerck, Saileta Prabhu, Leslie J. Dickmann, & Jennifer Sims. (2014). Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?. Drug Discovery Today. 19(10). 1623–1631. 120 indexed citations
8.
Kronenberg, Sven, Andreas Baumann, Lolke de Haan, et al.. (2013). Current challenges and opportunities in nonclinical safety testing of biologics. Drug Discovery Today. 18(23-24). 1138–1143. 18 indexed citations
9.
Horvath, Christopher, Laura Andrews, Andreas Baumann, et al.. (2012). Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial. Nature reviews. Immunology. 12(10). 740–740. 27 indexed citations
10.
Baumann, Andreas. (2009). Nonclinical development of biopharmaceuticals. Drug Discovery Today. 14(23-24). 1112–1122. 18 indexed citations
11.
Baumann, Andreas. (2008). Preclinical development of therapeutic biologics. Expert Opinion on Drug Discovery. 3(3). 289–297. 5 indexed citations
12.
Mould, Diane R., Andreas Baumann, Jens Kuhlmann, et al.. (2007). Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment response. British Journal of Clinical Pharmacology. 64(3). 278–291. 92 indexed citations
13.
Baumann, Andreas. (2005). Early Development of Therapeutic Biologics - Pharmacokinetics. Current Drug Metabolism. 7(1). 15–21. 76 indexed citations
14.
Högemann, Dagmar, et al.. (2000). In Vitro Model of the Human Liver Parenchyma to Study Hepatotoxic Side Effects of Dy-EOB-DTPA. Investigative Radiology. 35(6). 373–379. 9 indexed citations
15.
Baumann, Andreas, et al.. (1998). DNA Adduct Formation of Selected Sex Steroids in Human Liver Slices In Vitro. Toxicology in Vitro. 12(4). 353–364. 11 indexed citations
16.
Baumann, Andreas, et al.. (1996). Use of Rat and Human Liver Slices for the Detection of Steroid Hormone‐Induced DNA‐Adductsin vitroby Means of the32P‐Postlabeling Technique. Pharmacology & Toxicology. 78(4). 214–223. 21 indexed citations
17.
Baumann, Andreas, et al.. (1996). Comparative pharmacokinetics of two new steroidal estrogens and ethinylestradiol in postmenopausal women. Contraception. 54(4). 235–242. 8 indexed citations
18.
19.
Baumann, Andreas, et al.. (1992). Zur Wirkung von 2,4‐Dichlorphenol auf Enzymaktivitäten und andere Parameter in parenchymatösen Organen von Ratten. Food / Nahrung. 36(3). 273–278. 1 indexed citations
20.
Zschiesche, M & Andreas Baumann. (1989). Determination of the β-adrenoceptor blocking drug B24/76 in serum by high-performance liquid chromatography with fluorimetric detection after pre-column dansylation. Journal of Chromatography B Biomedical Sciences and Applications. 488(2). 482–486. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiajun Liu Breakdown of academic impact, for papers by Michèle Masquelier Breakdown of academic impact, for papers by Lisa M. Chelstrom Breakdown of academic impact, for papers by Jeff X. Zhou Breakdown of academic impact, for papers by Jun Ho Yi Breakdown of academic impact, for papers by Renta Hutabarat Breakdown of academic impact, for papers by Hans R. Hendriks Breakdown of academic impact, for papers by Lauren Price Breakdown of academic impact, for papers by Robert J. Fram Breakdown of academic impact, for papers by Xiaoke Huang
Rankless by CCL
2026